| Dr Catherine S Nelson, MD | |
|
601 Elmwood Ave, Rochester, NY 14642-8410 | |
| (585) 275-6500 | |
| (585) 276-1992 |
| Full Name | Dr Catherine S Nelson |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 18 Years |
| Location | 601 Elmwood Ave, Rochester, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457550030 | NPI | - | NPPES |
| 03500070 | Medicaid | NY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Arnot Ogden Medical Center | Elmira, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arnot Medical Services Pllc | 0840450748 | 140 |
| Arnot Ogden Medical Center | 5395798417 | 196 |
News Archive
The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable viruses to enter cells.
Telomeres, the repetitive sequences of DNA at the ends of linear chromosomes, have an important function: They protect vulnerable chromosome ends from molecular attack.
Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 7 days ago
| Entity Name | Arnot Ogden Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083605661 PECOS PAC ID: 5395798417 Enrollment ID: O20061003000664 |
News Archive
The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable viruses to enter cells.
Telomeres, the repetitive sequences of DNA at the ends of linear chromosomes, have an important function: They protect vulnerable chromosome ends from molecular attack.
Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 7 days ago
| Entity Name | Arnot Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427326768 PECOS PAC ID: 0840450748 Enrollment ID: O20120330000383 |
News Archive
The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable viruses to enter cells.
Telomeres, the repetitive sequences of DNA at the ends of linear chromosomes, have an important function: They protect vulnerable chromosome ends from molecular attack.
Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Catherine S Nelson, MD 601 Elmwood Ave, Box Surg, Rochester, NY 14642-8410 Ph: (585) 275-6500 | Dr Catherine S Nelson, MD 601 Elmwood Ave, Rochester, NY 14642-8410 Ph: (585) 275-6500 |
News Archive
The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable viruses to enter cells.
Telomeres, the repetitive sequences of DNA at the ends of linear chromosomes, have an important function: They protect vulnerable chromosome ends from molecular attack.
Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 7 days ago
Meghan C Little, PA-C Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 Red Creek Dr Ste 211, Rochester, NY 14623 Phone: 585-486-0600 | |
Irina Kanzafarova, MD Surgery Medicare: Medicare Enrolled Practice Location: 601 Elmwood Ave, Rochester, NY 14642 Phone: 585-273-1745 | |
Dr. Lael E Forbes, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1000 South Ave, Rochester, NY 14620 Phone: 585-341-6543 Fax: 585-341-6544 | |
Dr. Yanjie Qi, Surgery Medicare: Accepting Medicare Assignments Practice Location: 601 Elmwood Ave, Box Surg, Rochester, NY 14642 Phone: 585-275-3022 Fax: 585-276-7851 | |
Jacob Moalem, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 601 Elmwood Ave, Box Surg, Rochester, NY 14642 Phone: 585-275-1611 Fax: 585-273-1252 | |
Dustin John Fanciullo, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1445 Portland Ave, Suite 108, Rochester, NY 14621 Phone: 585-922-5550 Fax: 585-922-0450 | |
Mary Lou O'neill-huber, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 121 Erie Canal Dr, Suite B, Rochester, NY 14626 Phone: 585-225-5420 Fax: 585-225-5644 |